US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

38.52

+0.39001.02%

Post-market: 38.520.00000.00%19:30 EDT

Volume:44.36K

Turnover:1.70M

Market Cap:348.22M

PE:- -

High:38.52

Open:37.94

Low:37.94

Close:38.13

52wk High:39.80

52wk Low:30.66

Shares:9.04M

Float Shares:9.04M

Volume Ratio:0.86

T/O Rate:0.49%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Amgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Build

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology

EGFR Exon 20 Insertion Race Heats Up: Furmonertinib Files First-Line Indication as Two Domestic Contenders Prepare for Head-to-Head Battle

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/ORR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.52,"timestamp":1791576000000,"preClose":38.13,"halted":0,"volume":44362,"hourTrading":{"tag":"盘后","latestPrice":38.52,"preClose":38.52,"latestTime":"19:30 EDT","volume":8,"amount":308.16,"timestamp":1791588605827,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.010228166797797025,"floatShares":9040000,"shares":9040000,"eps":0,"marketStatus":"Market Closed","change":0.39,"latestTime":"10-09 16:00:00 EDT","open":37.94,"high":38.52,"low":37.94,"amount":1702969.3432399998,"amplitude":0.015211,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":38.13,"sharesOutstanding":12900000,"nav":37.91,"aum":342706400,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.52,"preClose":38.52,"latestTime":"19:30 EDT","volume":8,"amount":308.16,"timestamp":1791588605827,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8599119979102878,"impliedVol":0.1955,"impliedVolPercentile":0.6754},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9040000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.8599119979102878,"shares":9040000,"dividePrice":0,"high":38.52,"amplitude":0.015211,"preClose":38.13,"low":37.94,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":38.52,"eps":0,"divideRate":0,"volume":44362,"delay":0,"ttmEps":0,"open":37.94,"prevYearClose":34.16,"prevWeekClose":37.88,"prevMonthClose":37.77,"prevQuarterClose":37.77,"fiveDayClose":37.88,"twentyDayClose":38.8541,"sixtyDayClose":36.9435},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672923729","title":"Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2672923729","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672923729?lang=en_us&edition=fundamental","pubTime":"2026-10-04 03:40","pubTimestamp":1791056400,"startTime":"0","endTime":"0","summary":"Media Release COPENHAGEN, Denmark; October 3, 2026 Treatment with Rina-S 120 mg/m every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/03/3374111/0/en/genmab-announces-rinatabart-sesutecan-rina-s-phase-2-rainfol-01-results-demonstrated-durable-and-clinically-meaningful-responses-in-patients-with-platinum-resistant-ovarian-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029864427.USD","LU0868494617.USD","LU1974910355.USD","PROC","OC","NETL","IE00B2PGVK34.USD","BK4231","ORR","IE00BGHQF417.EUR","IE00B3CCJ633.GBP","LU0128525929.USD","LU2092937221.SGD","BK4086","LU0708994859.HKD","LU1267930573.SGD","LU2360108059.USD","BK4080","XHB","LU0310800379.SGD","ADC","BK4007","LU2298321311.HKD","LU2023250504.SGD","LU1917777945.USD","LU2106854487.HKD","LU2041044095.USD","LU2023250843.SGD","LU2048586759.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669646482","title":"Amgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Build","url":"https://stock-news.laohu8.com/highlight/detail?id=2669646482","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669646482?lang=en_us&edition=fundamental","pubTime":"2026-09-23 23:00","pubTimestamp":1790175600,"startTime":"0","endTime":"0","summary":"Amgen rebounds to $410.24 as dazodalibep and IMDELLTRA strengthen the pipeline while $418.73 becomes the next technical test.\n","market":"nz","thumbnail":"https://resource.tradingkey.com/uploads/20260923/AMGEN-82b57eea98fd4d6fa458e68c35b3ab95.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260923/AMGEN-82b57eea98fd4d6fa458e68c35b3ab95.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/analysis/stocks/us-stocks/262182585-stocks-amgen-stock-forecast-pipeline-410-breakout-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","07366","TSLY","TEST","BBH","PBE","LU2237443549.SGD","ELOL","TSLQ","AZN","TSLL","CRSH","07766","TSII","BGSX","ORR","09366","LU0868494617.USD","ORR.AU","BIB","LU1983299246.USD","TSL","TSLW","BK7095","TSDD","TLA","TSLS","IE0009355771.USD","TSLG","IE0002141913.USD","AZNH","TSYY","IBB","AMGN","TSLR","TSLP","IBBQ","TESL","TSLT","TESC","PJP","LU2242652126.USD","LU1061106388.HKD","LU2468319806.SGD","TBXU","TSLZ","TSLO","09766","LU1571399168.USD","TSLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669882142","title":"PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2669882142","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669882142?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078400,"startTime":"0","endTime":"0","summary":"39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor nave patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366230/37149/en/pds-biotech-announces-publication-of-versatile-002-phase-2-clinical-trial-results-of-pds0101-with-pembrolizumab-in-hpv16-positive-recurrent-and-or-metastatic-r-m-head-and-neck-canc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","BK4585","XBI","BK4588","ORR","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108925192","title":"EGFR Exon 20 Insertion Race Heats Up: Furmonertinib Files First-Line Indication as Two Domestic Contenders Prepare for Head-to-Head Battle","url":"https://stock-news.laohu8.com/highlight/detail?id=1108925192","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108925192?lang=en_us&edition=fundamental","pubTime":"2026-09-21 15:20","pubTimestamp":1789975238,"startTime":"0","endTime":"0","summary":"In the precision-targeted therapy space for non-small cell lung cancer (NSCLC), EGFR exon 20 insertion mutations (ex20ins) have long been viewed as one of the most difficult-to-treat niche targets...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","IPOS","BK4195","ORR","BK4211"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":29,"pageCount":1,"totalSize":116,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}